Summary & Overview
HCPCS G2000: Blinded Convulsive Therapy in IDE Clinical Trial
HCPCS Level II code G2000 designates a blinded administration of a convulsive therapy procedure performed per treatment session within an approved IDE-based clinical trial. The code covers either electroconvulsive therapy (ECT), recognized as a covered standard treatment, or magnetic seizure therapy (MST), characterized here as an experimental, non-covered intervention in the trial context. This distinction makes G2000 significant nationally as it documents trial-based delivery of high-acuity neurostimulation therapies and separates routine clinical care from investigational procedures.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the code, typical sites of service, and the implications for coding and billing when convulsive therapies are performed under an IDE-approved, blinded protocol. The publication outlines expected documentation elements, common modifiers in use (listed separately), and how payers commonly treat trial-based procedural claims. It also highlights benchmarks and policy considerations relevant to coverage distinctions between standard ECT and investigational MST within clinical trials. Data not available in the input are explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code G2000 describes a blinded administration of a convulsive therapy procedure performed per treatment session in an approved IDE-based clinical trial. The procedure may be either electroconvulsive therapy (ECT), which is a covered standard-of-care convulsive therapy, or magnetic seizure therapy (MST), which is described as an experimental, non-covered modality in this context.
Service Type: Convulsive therapy administered in a blinded clinical trial setting
Typical Site of Service: Hospital outpatient departments or specialized procedural suites where convulsive therapies are delivered under monitored conditions
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old with treatment-resistant major depressive disorder who is enrolled in an Institutional Review Board (IRB)-approved, Investigational Device Exemption (IDE) clinical trial comparing standard electroconvulsive therapy (ECT) with magnetic seizure therapy (MST). The patient undergoes a blinded treatment session in an ambulatory surgical center or inpatient psychiatric unit with general anesthesia administered by an anesthesiologist. Pre-procedure evaluation includes psychiatric assessment, medication reconciliation, informed consent for research and sedation, baseline cognitive screening, and pre-anesthesia clearance. On the day of service the patient is NPO as directed, intravenous access is established, and anesthesia induction is performed. A credentialed psychiatrist or authorized proceduralist delivers the convulsive therapy per protocol; either ECT (covered standard of care) or MST (study investigational arm, not covered outside trial) is applied. Continuous monitoring includes EEG and cardiorespiratory monitoring. Post-procedure recovery includes monitoring in a PACU or psychiatric recovery area until the patient meets discharge or transfer criteria. Documentation must indicate the blinded administration per protocol, trial identifiers, informed consent for participation in the IDE study, anesthesia details, device used, seizure parameters, EEG confirmation of adequate seizure, and any immediate adverse events. Billing uses G2000 reported once per treatment session, with adjunct CPT codes for anesthesia, E/M, or facility services billed separately as appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|